PCSK9 and type 2 diabetes mellitus: Notably, the addition of anti‐PCSK9 to statins in the FOURIER trial (using Evolocumab over a median of 2.2 years) (Sabatine et al., 2017) or in the ODYSSEY trial (using Alirocumab over a median of 2.8 years) (Ray et al., 2019) did not increase in the risk for T2D compared to statins alone.